Filing Flows › Maxcyte (MXCT) › Q2 2026 › vs Q1 2026
Maxcyte (MXCT) Q2 2026 vs Q1 2026 (quarter over quarter)
Maxcyte's revenue fell $2.4M (-25%) from $9.7M in Q1 2026 to $7.3M in Q2 2026. The biggest changes: Licenses −$2.9M (-53%); Product sales +$459K (+13%); Assay and other service revenue +$101K (+21%).
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product sales | $4.1M | $3.6M | $459K | +13% |
| Licenses | $2.6M | $5.5M | −$2.9M | -53% |
| Assay and other service revenue | $583K | $482K | $101K | +21% |
| Revenue | $7.3M | $9.7M | −$2.4M | -25% |
| Other income, net | $1.4M | $1.4M | −$77K | -5% |
| Net loss | $8.9M | $4.8M | $4.1M | +87% |
| Costs & expenses | $17.5M | $15.8M | $1.7M | +11% |
| Operating costs | $17.5M | $15.8M | $1.7M | +11% |
| Cost of revenue | $1.7M | $1.6M | $106K | +7% |
| Research & development | $4.3M | $3.9M | $396K | +10% |
| Sales & marketing | $3.4M | $3.4M | −$64K | -2% |
| General & admin | $7.3M | $6.0M | $1.3M | +22% |
| Other operating costs | $953K | $1.0M | −$63K | -6% |
| Operating cash sources | $8.9M | $4.8M | $4.1M | +87% |
| Depreciation & amortization | $978K | $1.0M | −$69K | -7% |
| Share-based compensation | $1.2M | $1.1M | $19K | +2% |
| Working capital & other | $2.1M | −$5.6M | $7.7M | — |
| Cash used in operations | $4.7M | $8.2M | −$3.5M | -43% |
| Net loss absorbed | $8.9M | $4.8M | $4.1M | +87% |
Questions
How much did Maxcyte's revenue grow quarter over quarter in Q2 2026?
Maxcyte's revenue fell $2.4M (-25%) from $9.7M in Q1 2026 to $7.3M in Q2 2026.
What drove Maxcyte's revenue change in Q2 2026?
Licenses −$2.9M (-53%); Product sales +$459K (+13%); Assay and other service revenue +$101K (+21%).